Skip to main content
SpringerLink
Log in

Experimental Therapeutics and Preclinical Models

  • Chapter
Book cover Neuroblastoma

Part of the book series: Pediatric Oncology ((PEDIATRICO))

  • 1315 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 159.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Backman U, Svensson A, Christofferson R (2002) Importance of vascular endothelial growth factor A in the progression of experimental neuroblastoma. Angiogenesis 5:267–274

    Article  PubMed  Google Scholar 

  • Bergman I, Barmada MA, Heller G, Griffin JA, Cheung NK (1999) Treatment of neoplastic meningeal xenografts by intraventricular administration of an antiganglioside monoclonal antibody 3F8. Int J Cancer 82:538–548

    Article  PubMed  Google Scholar 

  • Boland I, Vassal G, Morizet J, Terrier-Lacombe MJ, Valteau-Couanet D, Kalifa C, Hartmann O, Gouyette A (1999) Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations. Br J Cancer 79:787–792

    Article  PubMed  Google Scholar 

  • Brignole C, Pagnan G, Marimpietri D, Cosimo E, Allen TM, Ponzoni M, Pastorino F (2003) Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatment. Cancer Lett 197:231–235

    Article  PubMed  Google Scholar 

  • Brodeur GM (2002) Commentary on Kaneko et al.: Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. Int J Pediatr Hematol Oncol 24:608–609

    Article  Google Scholar 

  • Burkhart CA, Cheng AJ, Madafiglio J, Kavallaris M, Mili M, Marshall GM, Weiss WA, Khachigian LM, Norris MD, Haber M (2003) Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma. Int J Natl Cancer Inst 95:1394–1403

    Google Scholar 

  • Castel V, Canete A (2004) A comparison of current neuroblastoma chemotherapeutics. Exp Opin Pharmacother 5:71–80

    Article  Google Scholar 

  • Castel V, Canete A, Navarro S, Garcia-Miguel P, Melero C, Acha T, Navajas A, Badal MD (2001) Outcome of high-risk neuroblastoma using a dose intensity approach: improvement in initial but not in long-term results. Med Pediatr Oncol 37:537–542

    PubMed  Google Scholar 

  • Cheung NK, Modak S (2002) Oral (1→ 3),(1 →4)-β-D-glucan synergizes with anti-ganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin Cancer Res 8:1217–1223

    PubMed  Google Scholar 

  • Cheung NK, Landmeier B, Neely J, Nelson AD, Abramowsky C, Ellery S, Adams RB, Miraldi F (1986) Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2 specific monoclonal antibody against human neuroblastoma xenografted in nude mice. J Natl Cancer Inst 77:739–745

    PubMed  Google Scholar 

  • Donfrancesco A, Jenkner A, Castellano A, Ilari I, Milano GM, Sio L, de Cozza R, Fidani P, Deb G, de Laurentis C et al. (2004) Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/ cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age. Acta Paediatr (Suppl) 93:6–11

    Google Scholar 

  • Evans AE, Kisselbach KD, Yamashiro DJ, Ikegaki N, Camoratto AM, Dionne CA, Brodeur GM (1999) Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts. Clin Cancer Res 36:3594–3602

    Google Scholar 

  • Evans AE, Kisselbach KD, Liu X, Eggert A, Ikegaki N, Camoratto AM, Dionne C, Brodeur GM (2001) Effect of CEP-751 (KT-6587) on neuroblastoma xenografts expressing TrkB. Med Pediatr Oncol 5:181–184

    Article  Google Scholar 

  • Furman WL, Stewart CF, Poquette CA, Pratt CB, Santana VM, Zamboni WC, Bowman LC, Ma MK, Hoffer FA, Meyer WH et al. (1999) Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 171815–1824

    PubMed  Google Scholar 

  • Gilbert F, Tsao KL, LaLatta F, Xu L, Potluri VR, LaBadie G (1988) Human neuroblastoma metastases in a nude mouse model: tumor progression and onc gene amplification. Prog Clin Biol Res 271:17–29

    PubMed  Google Scholar 

  • Goldsby RE, Matthay KK (2004) Neuroblastoma: evolving therapies for a disease with many faces. Paediatr Drugs 6:107–122

    PubMed  Google Scholar 

  • Hackett CS, Hodgson JG, Law ME, Fridlyand J, Osoegawa K, de Jong PJ, Nowak NJ, Pinkel D, Albertson DG, Jain A et al. (2003) Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors. Cancer Res 63:5266–5273

    PubMed  Google Scholar 

  • Houghton PJ, Stewart CF, Zamboni WC, Thompson J, Luo X, Danks MK, and Houghton JA (1996) Schedule-dependent efficacy of camptothecins in models of human cancer. Ann NY Acad Sci 803:188–201

    PubMed  Google Scholar 

  • Houghton PJ, Cheshire PJ, Myers L, Stewart CF, Synold TW, Houghton JA (1992) Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 31:229–239

    Article  PubMed  Google Scholar 

  • Houghton PJ, Adamson PC, Blaney S, Fine HA, Gorlick R, Haber M, Helman L, Hirschfeld S, Hollingshead MG, Israel MA et al. (2002) Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res 8:3646–3657

    PubMed  Google Scholar 

  • Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E, Traxler P (2004) Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 64:2333–2337

    Article  PubMed  Google Scholar 

  • Imaizumi M, Watanabe A, Kikuta A, Takano T, Ito E, Shimizu T, Tsuchiya S, Iinuma K, Konno T, Ohi R, Hayashi Y (2001) Improved survival of children with advanced neuroblastoma treated by intensified therapy including myeloablative chemotherapy with stem cell transplantation: a retrospective analysis from the Tohoku Neuroblastoma Study Group. Tohoku J Exp Med 195:3–83

    Article  Google Scholar 

  • Ishizu H, Bove KE, Ziegler MM, Arya G (1994) Immune-mediated regression of “metastatic” neuroblastoma in the liver. J Pediatr Surg 29:55–160

    Article  Google Scholar 

  • Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, Kalyandrug S, Christian M, Arbuck S, Hollingshead M, Sausville EA (2001) Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 84:424–431

    Google Scholar 

  • Joseph JM, Bouquet C, Opolon P, Morizet J, Aubert G, Rossler J, Gross N, Griscelli F, Perricaudet M, Vassal G (2003) High level of stabilized angiostatin mediated by adenovirus delivery does not impair the growth of human neuroblastoma xenografts. Cancer Gene Ther 10:859–866

    Article  PubMed  Google Scholar 

  • Jouanneau E, Alberti L, Nejjari M, Treilleux I, Vilgrain I, Duc A, Combaret V, Favrot M, Leboulch P, Bachelot T (2001) Lack of antitumor activity of recombinant endostatin in a human neuroblastoma xenograft model. J Neurooncol 51:11–18

    Article  PubMed  Google Scholar 

  • Kaneko M, Tsuchida Y, Mugishima H, Ohnuma N, Yamamoto K, Kawa K, Iwafuchi M, Sawada T, Suita S (2002) Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. J Pediatr Hematol Oncol 24:613–621

    Article  PubMed  Google Scholar 

  • Katsanis E, Bausero MA, Panoskaltsis-Mortari A, Dancisak BB, Xu Z, Orchard PJ, Davis CG, Blazar BR (1996) Irradiation of singly and doubly transduced murine neuroblastoma cells expressing B7-1 and producing interferon-gamma reduces their capacity to induce systemic immunity. Cancer Gene Ther 3:75–82

    PubMed  Google Scholar 

  • Katzenstein HM, Rademaker AW, Senger C, Salwen HR, Nguyen NN, Thorner PS, Litsas L, Cohn SL (1999) Effectiveness of the angiogenesis inhibitor TNP-470 in reducing the growth of human neuroblastoma in nude mice inversely correlates with tumor burden. Clin Cancer Res 5:4273–4278

    PubMed  Google Scholar 

  • Khanna C, Jaboin JJ, Drakos E, Tsokos M, Thiele CJ (2002) Biologically relevant orthotopic neuroblastoma xenograft models: primary adrenal tumor growth and spontaneous distant metastasis. In Vivo 16:77–85

    PubMed  Google Scholar 

  • Kim ES, Serur A, Huang J, Manley CA, McCrudden KW, Frischer JS, Soffer SZ, Ring L, New T, Zabski S et al. (2002) Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci USA 99:11399–11404

    Article  PubMed  Google Scholar 

  • Kirstein MN, Houghton PJ, Cheshire PJ, Richmond LB, Smith AK, Hanna SK, Stewart CF (2001) Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts. Clin Cancer Res 7:358–366

    PubMed  Google Scholar 

  • Kuroiwa M, Ikeda H, Hongo T, Tsuchida Y, Hirato J, Kaneko Y, Suzuki N, Obana K, Makino SI (2001) Effects of recombinant human endostatin on a human neuroblastoma xenograft. Int J Mol Med 8:391–396

    PubMed  Google Scholar 

  • Leggas M, Stewart CF, Woo MH, Fouladi M, Cheshire PJ, Peterson JK, Friedman HS, Billups C, Houghton PJ (2002) Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts. Clin Cancer Res 8:3000–3007

    PubMed  Google Scholar 

  • Lode HN, Dreier T, Xiang R, Varki NM, Kang AS, Reisfeld RA (1998a) Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma. Proc Natl Acad Sci USA 95:2475–2480

    Article  PubMed  Google Scholar 

  • Lode HN, Reisfeld RA, Handgretinger R, Nicolaou KC, Gaedicke G, Wrasidlo W (1998b) Targeted therapy with a novel enediyene antibiotic calicheamicin theta(I)1 effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma. Cancer Res 58:2925–2928

    PubMed  Google Scholar 

  • Lode HN, Xiang R, Duncan SR, Theofilopoulos AN, Gillies SD, Reisfeld RA (1999) Tumor-targeted IL-2 amplifies T cellmediated immune response induced by gene therapy with single-chain IL-12. Proc Natl Acad Sci USA 96:8591–8596

    Article  PubMed  Google Scholar 

  • Martinez DA, Kahwash S, O''Dorisio MS, Lloyd TV, McGhee RB Jr, Qualman SJ (1996) Disseminated neuroblastoma in the nude rat. A xenograft model of human malignancy. Cancer 77:409–419

    Article  PubMed  Google Scholar 

  • Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP (1999) Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 341: 1165–1173

    Article  PubMed  Google Scholar 

  • Middlemas DS, Stewart CF, Kirstein MN, Poquette C, Friedman HS, Houghton PJ, Brent TP (2000) Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin Cancer Res 6:998–1007

    PubMed  Google Scholar 

  • Pertl U, Wodrich H, Ruehlmann JM, Gillies SD, Lode HN, Reisfeld RA (2003) Immunotherapy with a posttranscriptionally modified DNA vaccine induces complete protection against metastatic neuroblastoma. Blood 101:649–654

    Article  PubMed  Google Scholar 

  • Peterson JK, Houghton PJ (2004) Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer 40:837–844

    Article  PubMed  Google Scholar 

  • Phuangsab A, Lorence RM, Reichard KW, Peeples ME, Walter RJ (2001) Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. Cancer Lett 172:27–36

    Article  PubMed  Google Scholar 

  • Raffaghello L, Marimpietri D, Pagnan G, Pastorino F, Cosimo E, Brignole C, Ponzoni M, Montaldo PG (2003) Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse. Cancer Lett 197:205–209

    Article  PubMed  Google Scholar 

  • Redlinger RE Jr, Mailliard RB, Lotze MT, Barksdale EM Jr (2003a) Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo. J Pediatr Surg 38:301–307

    Article  PubMed  Google Scholar 

  • Redlinger RE Jr, Shimizu T, Remy T, Alber S, Watkins SC, Barksdale EM Jr (2003b) Cellular mechanisms of interleukin-12-mediated neuroblastoma regression. J Pediatr Surg 38:199–204

    Article  PubMed  Google Scholar 

  • Ribatti D, Raffaghello L, Pastorino F, Nico B, Brignole C, Vacca A, Ponzoni M (2002) In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression. Int J Cancer 102:351–354

    Article  PubMed  Google Scholar 

  • Santana VM, Zamboni WC, Kirstein MN, Tan M, Liu T, Gajjar A, Houghton PJ, Stewart CF (2003) A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin Cancer Res 9:633–640

    PubMed  Google Scholar 

  • Shusterman S, Grupp SA, Maris JM (2000) Inhibition of tumor growth in a human neuroblastoma xenograft model with TNP-470. Med Pediatr Oncol 35:673–676

    Article  PubMed  Google Scholar 

  • Shusterman S, Grupp SA, Barr R, Carpentieri D, Zhao H, Maris JM (2001) The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. Clin Cancer Res 7:977–984

    PubMed  Google Scholar 

  • Siapati KE, Barker S, Kinnon C, Michalski A, Anderson R, Brickell P, Thrasher AJ, Hart SL (2003) Improved antitumour immunity in murine neuroblastoma using a combination of IL-2 and IL-12. Br J Cancer 88:1641–1648

    Article  PubMed  Google Scholar 

  • Soto LJ III, Sorenson BS, Nelson BW, Solis SJ, Leonard AS, Saltzman DA (eds) (2004) Preferential proliferation of attenuated Salmonella typhimurium within neuroblastoma. J Pediatr Surg 39:937–940

    Google Scholar 

  • Stewart CF, Leggas M, Schuetz JD, Panetta JC, Cheshire PJ, Peterson J, Daw N, Jenkins JJ III, Gilbertson R, Germain GS, Harwood FC, Houghton PJ (2004) Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res 64:7491–7499

    Article  PubMed  Google Scholar 

  • Thompson J, Zamboni WC, Cheshire PJ, Lutz L, Luo X, Li Y, Houghton JA, Stewart CF, Houghton PJ (1997) Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin Cancer Res 3:423–431

    PubMed  Google Scholar 

  • Thompson J, Guichard SM, Cheshire PJ, Richmond LB, Poquette CA, Ragsdale ST, Webber B, Lorsbach R, Danks MK, Houghton PJ (2001) Development, characterization and therapy of a disseminated model of childhood neuroblastoma in SCID mice. Cancer Chemother Pharmacol 47:211–221

    Article  PubMed  Google Scholar 

  • Tsuchida Y, Yokomori K, Iwanaka T, Saito S (1984) Nude mouse xenograft study for treatment of neuroblastoma: effects of chemotherapeutic agents and surgery on tumor growth and cell kinetics. J Pediatr Surg 19:72–76

    PubMed  Google Scholar 

  • Tsuchida Y, Shitara T, Kuroiwa M, Ikeda H (2003) Current treatment and future directions in neuroblastoma. Indian J Pediatr 70:809–812

    PubMed  Google Scholar 

  • Turner WJ, Chatten J, Lampson LA (1990) Human neuroblastoma cell growth in xenogeneic hosts: comparison of T cell-deficient and NK-deficient hosts, and subcutaneous or intravenous injection routes. J Neurooncol 8:121–132

    Article  PubMed  Google Scholar 

  • Valteau-Couanet D, Benhamou E, Vassal G, Stambouli F, Lapierre V, Couanet D, Lumbroso J, Hartmann O (2000) Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma. Bone Marrow Transplant 25:937–942

    Article  PubMed  Google Scholar 

  • Vertuani S, de Geer A, Levitsky V, Kogner P, Kiessling R, Levitskaya J (2003) Retinoids act as multistep modulators of the major histocompatibility class I presentation pathway and sensitize neuroblastomas to cytotoxic lymphocytes. Cancer Res 63:8006–8013

    PubMed  Google Scholar 

  • Wagner LM, Guichard SM, Burger RA, Morton CL, Straign CM, Ashmun RA, Harris LC, Houghton PJ, Potter PM, Danks MK (2002) Efficacy and toxicity of a virus-directed enzyme prodrug therapy purging method: preclinical assessment and application to bone marrow samples from neuroblastoma patients. Cancer Res 62:5001–5007

    PubMed  Google Scholar 

  • Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM (1997) Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 16:2985–2995

    Article  PubMed  Google Scholar 

  • Weiss WA, Godfrey T, Francisco C, Bishop JM (2000) Genomewide screen for allelic imbalance in a mouse model for neuroblastoma. Cancer Res 60:2483–2487

    PubMed  Google Scholar 

  • Wierdl M, Wall A, Morton CL, Sampath J, Danks MK, Schuetz JD, Potter PM (2003) Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot override ABCG2-mediated drug resistance. Mol Pharmacol 64:279–288

    Article  PubMed  Google Scholar 

  • Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS, Park JW (2003). YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 95:516–525

    PubMed  Google Scholar 

  • Zamboni WC, Stewart CF, Thompson J, Santana VM, Cheshire PJ, Richmond LB, Luo X, Poquette C, Houghton JA, Houghton PJ (1998) Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J Natl Cancer Inst 90:505–511

    Article  PubMed  Google Scholar 

  • Ziegler MM, Ishizu H, Nagabuchi E, Takada N, Arya G (1997) A comparative review of the immunobiology of murine neuroblastoma and human neuroblastoma. Cancer 79:1757–1766

    Article  PubMed  Google Scholar 

Download references

Authors
  1. Jennifer K. Peterson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter J. Houghton
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10021, USA

    Nai-Kong V. Cheung MD, PhD

  2. Department of Pediatrics and the Comprehensive Robert H. Lurie Cancer Center, Northwestern University, 2300 Children's Plaza, Chicago, IL, 60614, USA

    Susan L. Cohn MD

  3. Feinberg School of Medicine, Children's Memorial Hospital, 2300 Children's Plaza, Chicago, IL, 60614, USA

    Susan L. Cohn MD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Peterson, J.K., Houghton, P.J. (2005). Experimental Therapeutics and Preclinical Models. In: Cheung, NK.V., Cohn, S.L. (eds) Neuroblastoma. Pediatric Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-26616-X_17

Download citation

  • DOI: https://doi.org/10.1007/3-540-26616-X_17

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-40841-3

  • Online ISBN: 978-3-540-26616-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation